Fig. 2
From: Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer
H89/cAMP confers susceptibility or resistance to ferroptosis. A, B Relative viability of A549 and H1299 cells treated with RSL3 (ferroptosis inducer, 2 μM), RSL3 (2 μM) plus DFO (ferroptosis inhibitor, 100 μM), RSL3 (2 μM) plus ferr-1 (ferroptosis inhibitor, 10 μM), RSL3 (2 μM) plus Z-VAD-FMK (apoptosis inhibitor, 10 μM), or RSL3 (2 μM) plus Necro (necroptosis inhibitor, 0.5 μM) after incubating with DMSO, H89 (30 μM) or cAMP (100 μM) for 48 h. C, D The lipid peroxidation level of A549 and H1299 cells detected by BODIPY-C11 dye while treated with RSL3 (2 μM), RSL3 (2 μM) plus DFO (100 μM), RSL3 (2 μM) plus ferr-1 (10 μM), RSL3 (2 μM) plus Z-VAD-FMK (10 μM), or RSL3 (2 μM) plus Necro (0.5 μM) after incubating with H89 (30 μM) or cAMP (100 μM) for 48 h. E Measurement of MDA production of A549 and H1299 cells incubating with RSL3 (2 μM) for 8 h after pre-treatment with DMSO, H89 (30 μM), or cAMP (100 μM) for 48 h. DFO, deferoxamine; ferr-1,ferrostatin-1; Z-VAD-FMK, Z-VAD (OMe)-FMK; Necro, Necrosulfonamide; MDA, malondialdehyde. The data are presented as the mean ± SD from three biological replicates. ns, not significant; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001